The company’s lead drug, izokibep, missed its goal in a late-stage trial, though Acelyrin said it sees some hope in the results.Dive Brief:Acelyrin lost more than half its market value Tuesday morning after the biotechnology company’s lead drug failed in an closely watched Phase 2b/3 trial.The results come from one of several late-stage studies of […]
